AGM Statement

Oxford Biomedica PLC
10 May 2005




FOR IMMEDIATE RELEASE                                                10 MAY 2005








                  OXFORD BIOMEDICA ANNUAL GENERAL MEETING 2005

Oxford, UK: 10 May 2005 - At Oxford BioMedica's Annual General Meeting, held
today in London, all resolutions were duly passed.

                                     -Ends-


For further information, please contact:
Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive                                      Tel: [phone]
City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan                         Tel: [phone]
Communications
Scientific/Trade Press Enquiries

Sue Charles/ Katja Stout/ Ashley Lilly                                        Tel: [phone]

Northbank Communications



Notes to editors:



1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.



Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical trials in early 2006, and four
further preclinical candidates. The Company is underpinned by over 80 patent
families, which represent one of the broadest patent estates in the field.



The Company has a staff of approximately 65 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham,
Viragen, MolMed and Kiadis; and has licensed technology to a number of companies
including Merck & Co and Biogen Idec.



Further information is available at www.oxfordbiomedica.co.uk.




                      This information is provided by RNS
            The company news service from the London Stock Exchange